In Vitro Activity of Eravacycline and Comparator Agents Against Bacterial Pathogens Isolated From Patients With Cancer

Authors

Kenneth Rolston
Bahgat Gerges
Lior Nesher
Samuel A Shelburne
Randall Prince
Issam Raad

Publication Date

4-1-2023

Journal

JAC-Antimicrobial Resistance

DOI

10.1093/jacamr/dlad020

PMID

36875177

PMCID

PMC9981869

PubMedCentral® Posted Date

March 2023

PubMedCentral® Full Text Version

Post-print

Abstract

BACKGROUND: Bacterial infections are common in patients with cancer, and many bacteria have developed resistance to currently used antibiotics.

OBJECTIVES: We evaluated the

METHODS: Antimicrobial susceptibility testing was performed using CLSI-approved methodology and interpretive criteria for 255 Gram-positive and 310 Gram-negative bacteria. MIC and susceptibility percentage were calculated according to CLSI and FDA breakpoints when available.

RESULTS: Eravacycline had potent activity against most Gram-positive bacteria, including MRSA. Of 80 Gram-positive isolates with available breakpoints, 74 (92.5%) were susceptible to eravacycline. Eravacycline had potent activity against most Enterobacterales, including ESBL-producing organisms. Of 230 Gram-negative isolates with available breakpoints, 201 (87.4%) were susceptible to eravacycline. Eravacycline had the best activity among comparators against carbapenem-resistant Enterobacterales, with 83% susceptibility. Eravacycline was also active against many non-fermenting Gram-negative bacteria, with the lowest MIC

CONCLUSIONS: Eravacycline was active against many clinically significant bacteria isolated from patients with cancer, including MRSA, carbapenem-resistant Enterobacterales, and non-fermenting Gram-negative bacilli. Eravacycline might play an important role in the treatment of bacterial infections in patients with cancer, and additional clinical evaluation is warranted.

Published Open-Access

yes

Recommended Citation

Rolston, Kenneth; Gerges, Bahgat; Nesher, Lior; et al., "In Vitro Activity of Eravacycline and Comparator Agents Against Bacterial Pathogens Isolated From Patients With Cancer" (2023). Faculty, Staff and Student Publications. 2014.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/2014